Ineffectiveness of topiramate and levetiracetam in infantile spasms non-responsive to steroids: Open labeled randomized prospective study

Neurosciences

Volumn 18, Issue 2, 2013, Pages 143-146

  Mahmoud, Adel A ^a   Rizk, Tamer M ^b   Mansy, Ahmed A ^a   Ali, Jaffar A ^a   Al Tannir, Mohamad A ^a  

^a King Abdullah International Medical Research Center College of Public Health and Health Informatics   (Saudi Arabia)

^b KING FAHAD MEDICAL CITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM; PREDNISONE; STEROID; TOPIRAMATE;

ARTICLE; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; INFANT; INFANTILE SPASM; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAUDI ARABIA; SEIZURE; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 84922687140     PISSN: 13196138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Mackay M, Weiss S, Snead OC 3rd. Treatment of infantile spasms: an evidence-based approach. Int Rev Neurobiol 2002; 49: 157-184.
2. Mackay MT, Weiss SK, Adams-Webber T, Ashwal S, Stephens D, Ballaban-Gill K, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004; 62: 1668-1681.
3. Wild JM, Robson CR, Jones AL, Cunliffe IA, Smith PE. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest Ophthalmol Vis Sci 2006; 47: 917-924.
4. Horton M, Rafay M, Del Bigio MR. Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration. J Child Neurol 2009; 24: 1543-1546.
5. Lane SD, Gowin JL, Green CE, Steinberg JL, Moeller F, Cherek DR. Acute topiramate differentially affects human aggressive responding at low vs. moderate doses in subjects with histories of substance abuse and antisocial behavior. Pharmacol Biochem Behav 2009; 92: 357-362.
6. Rosenfeld WE, Berkovic S, Knowlton R on behalf of Lev N01057 PGTC Study Group. Efficacy and Safety of Levetiracetam 3000 mg/day (Pediatric Dose 60 mg/kg/day) as Adjunctive Therapy in Adult and Pediatric Idiopathic Generalized Epilepsy Patients Experiencing Primary Generalized Tonic-Clonic Seizures (Poster Presentation). Proceedings of the 1st North American Regional Epilepsy Congress; 2006 Dec 1-5; San Diego (CA).
7. Reis J, Wentrup A, Hamer HM, Mueller HH, Knake S, Tergau F, et al. Levetiracetam influences human motor cortex excitability mainly by modulation of ion channel function--a TMS study. Epilepsy Res 2004; 62: 41-51.
8. Glauser TA, Clark PO, McGee K. Long-term response to topiramate in patients with West syndrome. Epilepsia 2000; 41 Suppl 1: S91-S94.
9. Grosso S, Cordelli DM, Franzoni E, Coppola G, Capovilla G, Zamponi N, et al. Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy. Seizure 2007; 16: 345-350.
10. Mahmoud AA, Rizk T, El-Bakri NK, Riaz M, Dannawi S, Al Tannir M. Incidence of kidney stones with topiramate treatment in pediatric patients. Epilepsia 2011; 52: 1890-1893.
11. Hosain S, Nikalov B, Harden C, Li M, Fraser R, Labar D. Vagus nerve stimulation treatment for Lennox-Gastaut syndrome. J Child Neurol 2000; 15: 509-512.
12. Ritter F, Glauser TA, Elterman RD, Wyllie E. Effectiveness, tolerability, and safety of topiramate in children with partialonset seizures. Topiramate YP Study Group. Epilepsia 2000; 41 Suppl 1: S82-S85.
13. Hrachovy RA, Frost JD Jr. Infantile spasms. Pediatr Clin North Am 1989; 36: 311-329.
14. Lawlor KM, Devlin AM. Levetiracetam in the treatment of infantile spasms. Eur J Paediatr Neurol 2005; 9: 19-22.